RT Journal Article
SR Electronic
T1 Nationwide rollout reveals efficacy of epidemic control through digital contact tracing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.27.21252577
DO 10.1101/2021.02.27.21252577
A1 Ahmed Elmokashfi
A1 Joakim Sundnes
A1 Amund Kvalbein
A1 Valeriya Naumova
A1 Sven-Arne Reinemo
A1 Per Magne Florvaag
A1 Håkon Kvale Stensland
A1 Olav Lysne
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.27.21252577.abstract
AB Fueled by epidemiological studies of SARS-CoV-2, contact tracing by mobile phones has been put to use in many countries. A year into the pandemic, we lack conclusive evidence on its effectiveness. Here, we used a unique real world contact data set, collected during the rollout of the first Norwegian contact tracing app in the Spring of 2020, to address this gap. Our dataset involves millions of contacts between 12.5% of the adult population, and enabled us to measure the real-world app performance. The technological tracing efficacy was measured at 80%, and we estimated that at least 11.0% of the discovered close contacts could not be identified by manual contact tracing. The overall effectiveness of digital tracing depends strongly on app uptake, but significant impact can be achieved for moderate uptake numbers. Used as a supplement to manual tracing and other measures, digital tracing can be instrumental in controlling the pandemic. Our findings can thus help informing public health policies in the coming months.Competing Interest StatementSimula Research Laboratory led the development of Smittestopp at the request of the Norwegian government. The authors were all involved in some capacity. This involvement stopped in August after the suspension of Smittestopp.Funding StatementThis work was funded by Simula Research Laboratory. A.E and O.L. were partially funded by the Center for Resilient Networks and Application, a research center of excellence that is funded by the Norwegian Ministry of Local Government and Modernization.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human subject data was aggregated and anonymized in accordance with the privacy policy of Smittestopp and is approved by the Norwegian Institute of Public Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and scripts for the efficacy model, the impact of uptake on pandemic progression and analysis of the ENS are available at the link below. Correspondence and requests for materials and datasets that are not yet public should be addressed to Ahmed Elmokashfi. https://github.com/sundnes/smittestopp_data_model